Profile data is unavailable for this security.
About the company
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
- Revenue in USD (TTM)0.00
- Net income in USD-42.55m
- Incorporated2018
- Employees56.00
- LocationPulse Biosciences Inc3957 Point Eden WayHAYWARD 94545-3720United StatesUSA
- Phone+1 (510) 906-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.pulsebiosciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Orthopediatrics Corp | 161.83m | -21.97m | 802.32m | 247.00 | -- | 2.14 | -- | 4.96 | -0.9647 | -0.9647 | 7.11 | 15.74 | 0.3748 | 0.4247 | 5.13 | 655,178.10 | -5.09 | -5.40 | -5.62 | -5.93 | 74.07 | 75.09 | -13.58 | -15.92 | 1.99 | -- | 0.0271 | -- | 21.62 | 20.91 | -1,767.25 | -- | 28.29 | -- |
Atrion Corp | 176.67m | 18.72m | 805.58m | 712.00 | 43.05 | 3.33 | 23.52 | 4.56 | 10.63 | 10.63 | 100.32 | 137.46 | 0.6794 | 1.56 | 7.93 | 248,127.80 | 7.20 | 11.96 | 7.63 | 12.62 | 33.77 | 41.99 | 10.60 | 19.05 | 3.06 | -- | 0.00 | 42.42 | -7.73 | 2.12 | -44.55 | -10.74 | 4.98 | 11.27 |
Simulations Plus Inc | 66.98m | 9.65m | 811.71m | 192.00 | 85.58 | 4.49 | 57.40 | 12.12 | 0.474 | 0.474 | 3.29 | 9.04 | 0.3603 | -- | 5.57 | 348,843.80 | 5.19 | 7.20 | 5.49 | 7.61 | 72.53 | 77.61 | 14.40 | 21.29 | -- | -- | 0.00 | 45.70 | 10.52 | 14.96 | -20.20 | 6.02 | 12.91 | 0.8548 |
Cytek Biosciences Inc | 200.79m | -11.51m | 817.83m | 637.00 | -- | 2.08 | -- | 4.07 | -0.0856 | -0.0856 | 1.50 | 2.99 | 0.395 | 1.44 | 4.30 | 297,020.70 | -2.26 | -- | -2.54 | -- | 55.48 | -- | -5.73 | -- | 6.01 | -- | 0.0086 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
Standard Biotools Inc | 126.76m | -135.98m | 839.72m | 534.00 | -- | 1.50 | -- | 6.62 | -0.9957 | -0.9957 | 0.9537 | 1.52 | 0.2206 | 2.05 | 5.02 | 237,380.20 | -15.66 | -28.17 | -18.29 | -33.60 | 49.15 | 51.58 | -70.98 | -74.85 | 4.17 | -- | 0.0869 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
Embecta Corp | 1.13bn | 70.20m | 935.41m | 2.20k | 13.34 | -- | 8.84 | 0.826 | 1.22 | 1.22 | 19.62 | -13.35 | 0.94 | 2.51 | 15.86 | 514,772.70 | 5.83 | -- | 8.06 | -- | 65.57 | -- | 6.20 | -- | 1.79 | 2.03 | 1.89 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
Avanos Medical Inc | 680.10m | -1.60m | 1.04bn | 3.77k | -- | 0.8516 | 23.79 | 1.53 | -0.0315 | -1.33 | 14.62 | 26.65 | 0.4005 | 1.62 | 5.48 | 180,350.00 | -0.0942 | -0.6527 | -0.1055 | -0.7338 | 56.33 | 54.45 | -0.2353 | -1.60 | 1.47 | 4.85 | 0.1257 | -- | -1.58 | 0.6357 | -146.05 | -- | -18.37 | -- |
BioLife Solutions Inc | 137.30m | -62.93m | 1.05bn | 409.00 | -- | 3.12 | -- | 7.64 | -1.43 | -1.43 | 3.10 | 7.30 | 0.3238 | 2.17 | 5.61 | 335,687.00 | -14.84 | -13.76 | -16.52 | -15.04 | 32.97 | 36.76 | -45.84 | -42.99 | 1.77 | -32.08 | 0.0717 | -- | -11.43 | 48.65 | 52.49 | -- | 86.35 | -- |
Pulse Biosciences Inc | 0.00 | -42.55m | 1.07bn | 56.00 | -- | 26.56 | -- | -- | -0.8152 | -0.8152 | 0.00 | 0.6571 | 0.00 | -- | -- | 0.00 | -71.28 | -93.21 | -79.29 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
Silk Road Medical Inc | 185.49m | -53.42m | 1.07bn | 474.00 | -- | 7.24 | -- | 5.79 | -1.37 | -1.37 | 4.76 | 3.73 | 0.7247 | 2.08 | 7.87 | 391,322.80 | -20.87 | -29.02 | -22.75 | -32.98 | 73.31 | 72.91 | -28.80 | -46.84 | 9.62 | -- | 0.34 | -- | 27.77 | 38.66 | -1.33 | -- | -7.92 | -- |
Figs Inc | 544.71m | 22.16m | 1.14bn | 354.00 | 54.20 | 2.93 | 44.99 | 2.10 | 0.1238 | 0.1238 | 3.00 | 2.29 | 1.21 | 1.10 | 118.49 | 1,538,720.00 | 4.93 | -- | 5.72 | -- | 68.56 | -- | 4.07 | -- | 3.83 | -- | 0.00 | -- | 7.87 | -- | 6.85 | -- | -- | -- |
Artivion Inc | 368.21m | -9.58m | 1.16bn | 1.50k | -- | 3.95 | 85.42 | 3.16 | -0.2615 | -0.2615 | 8.64 | 7.07 | 0.4779 | 1.64 | 5.37 | 245,470.70 | -1.25 | -2.20 | -1.33 | -2.36 | 64.75 | 65.51 | -2.61 | -5.34 | 4.26 | 2.47 | 0.5176 | -- | 12.82 | 6.14 | -60.09 | -- | 5.13 | -- |
AtriCure Inc | 414.60m | -37.23m | 1.20bn | 1.20k | -- | 2.62 | -- | 2.89 | -0.8005 | -0.8005 | 8.92 | 9.43 | 0.7059 | 1.70 | 8.21 | 345,501.70 | -6.34 | -3.72 | -7.08 | -4.10 | 75.26 | 74.36 | -8.98 | -7.64 | 2.83 | -10.27 | 0.1212 | -- | 20.84 | 14.64 | 34.49 | -- | 46.56 | -- |
Owens & Minor, Inc. | 10.42bn | -38.77m | 1.26bn | 13.70k | -- | 1.41 | 5.01 | 0.121 | -0.5099 | -0.5099 | 136.98 | 11.71 | 1.98 | 6.79 | 14.60 | 760,861.20 | -0.7372 | 1.32 | -1.11 | 2.07 | 20.75 | 16.48 | -0.3719 | 0.5614 | 0.5648 | 2.19 | 0.7065 | 0.798 | 3.80 | 1.87 | -284.47 | -- | 25.91 | -- |
Establishment Labs Holdings Inc | 155.79m | -82.76m | 1.32bn | 781.00 | -- | 23.18 | -- | 8.48 | -3.15 | -3.15 | 5.91 | 2.07 | 0.6095 | 0.9191 | 3.39 | 171,579.30 | -32.38 | -33.22 | -39.25 | -41.12 | 65.01 | 64.73 | -53.12 | -43.19 | 2.73 | -21.30 | 0.7715 | -- | 2.13 | 21.96 | -4.38 | -- | 69.16 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 956.33k | 1.73% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 827.67k | 1.50% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 777.13k | 1.41% |
Geode Capital Management LLCas of 31 Mar 2024 | 390.96k | 0.71% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 349.74k | 0.63% |
Griffin Asset Management, Inc.as of 31 Mar 2024 | 300.32k | 0.54% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 187.14k | 0.34% |
Spotlight Asset Group, Inc.as of 31 Mar 2024 | 72.09k | 0.13% |
Westside Investment Management LLCas of 30 Jun 2024 | 63.60k | 0.12% |
Renaissance Technologies LLCas of 31 Mar 2024 | 61.40k | 0.11% |